PMID- 10828051
OWN - NLM
STAT- MEDLINE
DCOM- 20000629
LR  - 20210216
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 95
IP  - 11
DP  - 2000 Jun 1
TI  - Effect of leukocyte compatibility on neutrophil increment after transfusion of 
      granulocyte colony-stimulating factor-mobilized prophylactic granulocyte 
      transfusions and on clinical outcomes after stem cell transplantation.
PG  - 3605-12
AB  - The primary limitations of granulocyte transfusions include low component cell 
      dose and leukocyte incompatibility. Component cell dose improved with granulocyte 
      colony-stimulating factor (G-CSF) mobilization, and the transfusion of 
      G-CSF-mobilized, human leukocyte antigen (HLA)-matched granulocyte components 
      resulted in significant, sustained absolute neutrophil count (ANC) increments. 
      However, the effect of leukocyte compatibility on outcomes with G-CSF-mobilized 
      granulocyte transfusions is unclear. The objectives were to determine the effect 
      of leukocyte compatibility on ANC increments and selected clinical outcomes after 
      transfusion of prophylactic, G-CSF-mobilized granulocyte components into 
      neutropenic recipients of autologous peripheral blood stem cell (PBSC) 
      transplants. Beginning on transplant day 2, 23 evaluable recipients were 
      scheduled to receive 4 alternate-day transfusions of granulocyte components 
      apheresed from a single donor given G-CSF. G-CSF was also given to recipients 
      after transplantation. Recipient ANC was determined before and sequentially after 
      each granulocyte transfusion to determine the peak ANC increment. Leukocyte 
      compatibility was determined at study entry only by a lymphocytotoxicity 
      screening assay (s-LCA) against a panel of HLA-defined cells. Eight recipients 
      had positive s-LCA. On days 2 and 4, the mean peak ANC increments after 
      granulocyte transfusion were comparable between the cohorts with positive and 
      negative s-LCA. However, the mean peak ANC increments on day 6 (246/microL vs 
      724/microL; P =.05) and day 8 (283/microL vs 1079/microL; P =.06) were lower in 
      the cohort with positive s-LCA, in spite of the transfusion of comparable 
      component cell doses. Adverse reactions occurred with only 5 of 87 (5.7%) 
      granulocyte transfusions and were not associated with leukocyte compatibility 
      test results. Platelet increments, determined 1 hour after granulocyte 
      transfusion, were comparable between the cohorts. Although the 2 cohorts received 
      PBSC components with similar CD34(+) cell doses, the cohort with a positive s-LCA 
      had delayed neutrophil engraftment and a greater number of febrile days and 
      required more days of intravenous antibiotics and platelet transfusions. 
      Leukocyte incompatibility adversely affected ANC increments after the transfusion 
      of G-CSF-mobilized granulocyte components and clinical outcomes after PBSC 
      transplantation.
FAU - Adkins, D R
AU  - Adkins DR
AD  - Department of Internal Medicine, Division of Bone Marrow Transplantation and Stem 
      Cell Biology, Washington University School of Medicine, St Louis, MO 63110-1093, 
      USA.
FAU - Goodnough, L T
AU  - Goodnough LT
FAU - Shenoy, S
AU  - Shenoy S
FAU - Brown, R
AU  - Brown R
FAU - Moellering, J
AU  - Moellering J
FAU - Khoury, H
AU  - Khoury H
FAU - Vij, R
AU  - Vij R
FAU - DiPersio, J
AU  - DiPersio J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (ABO Blood-Group System)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
SB  - IM
MH  - ABO Blood-Group System
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Blood Donors
MH  - Female
MH  - Granulocyte Colony-Stimulating Factor/adverse effects/*therapeutic use
MH  - Granulocytes/*transplantation
MH  - *Hematopoietic Stem Cell Mobilization
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Hematopoietic Stem Cells/*cytology/drug effects
MH  - *Histocompatibility Testing
MH  - Humans
MH  - Leukapheresis
MH  - Leukocyte Count
MH  - *Leukocyte Transfusion
MH  - Male
MH  - Middle Aged
MH  - Neutrophils/*physiology
MH  - Nuclear Family
MH  - Treatment Outcome
EDAT- 2000/05/29 09:00
MHDA- 2000/07/06 11:00
CRDT- 2000/05/29 09:00
PHST- 2000/05/29 09:00 [pubmed]
PHST- 2000/07/06 11:00 [medline]
PHST- 2000/05/29 09:00 [entrez]
AID - S0006-4971(20)64033-2 [pii]
PST - ppublish
SO  - Blood. 2000 Jun 1;95(11):3605-12.